Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao

Blood (2024) 144 (Supplement 1): 6553.

https://doi.org/10.1182/blood-2024-203842

Published: 2024

Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4502.3.

https://doi.org/10.1182/blood-2024-204749

Published: 2024

Journal Articles

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Yue Wang, Xue Wang, Xinyun Huang, Ying Qian, Rongji Mu, Qing Shi, Di Fu, Hongmei Yi, Bin-Shen Ou-Yang, Zhuo Han Li, Shu Cheng, Wang Li, Ning Wen, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2024-206537

Published: 2024

Journal Articles

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Yi-Lun Zhang, Lingshuang Sheng, Rong Shen, Wen Wu, Xin Zheng, Li Wang, Shu Cheng, Peng-Peng Xu, Qi-Jie Jian, Bo Peng, Ke Zhang, Fei Pang, Kai Wang, Zi-Xun Yan, Wei-Li Zhao

Blood (2024) 144 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2024-209889

Published: 2024

Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao

Blood (2024) 144 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2024-204775

Published: 2024

Journal Articles

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

Jie Xiong, Shu Cheng, Hua-man Cai, Yu-Ran Qiu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2024-206718

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Yige Shen, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2023-188042

Published: 2023

Journal Articles

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Yige Shen, Yiwen Cao, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 3091.

https://doi.org/10.1182/blood-2023-182603

Published: 2023

Journal Articles

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Wang Li, Shu Cheng, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2023-186087

Published: 2023

Journal Articles

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Li Wang, Shu Cheng, Wei Li Zhao

Blood (2021) 138 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2021-146851

Published: 2021

Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 4083.

https://doi.org/10.1182/blood-2019-126408

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Zixun Yan, Wen Wang, MD, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2018-99-115769

Published: 2018

Journal Articles

Chidamide Plus R-CHOP21 in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Muchen Zhang, Ying Fang, Pengpeng Xu, Shu Cheng, Li Wang, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2018-99-113942

Published: 2018

Journal Articles

A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis

Pengpeng Xu, Muchen Zhang, Ying Fang, Li Wang, Shu Cheng, Wei-li Zhao

Blood (2017) 130 (Supplement 1): 4126.

https://doi.org/10.1182/blood.V130.Suppl_1.4126.4126

Published: 2017

NARROW

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Chidamide Plus R-CHOP21 in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only